Human Apolipoprotein CIII ELISA Kit (APOC3) (ab154131)
Key features and details
- Sensitivity: 105 µg/ml
- Sample type: Cell culture supernatant, Cerebral Spinal Fluid, Milk, Plasma, Serum, Urine
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Human Apolipoprotein CIII ELISA Kit (APOC3)
See all Apolipoprotein CIII kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall 5.64% Inter-assay Sample n Mean SD CV% Overall 11% -
Sample type
Cell culture supernatant, Milk, Urine, Serum, Plasma, Cerebral Spinal Fluid -
Assay type
Sandwich (quantitative) -
Sensitivity
105 µg/ml -
Recovery
99 %
-
Assay time
4h 00m -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Human Apolipoprotein CIII (APOC3) in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit (ab154131) is designed for the quantitative measurement of APOC3 in plasma, serum, urine, milk, CSF, and cell culture samples.
An Apolipoprotein CIII specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently an Apolipoprotein CIII specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Conjugate is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Apolipoprotein CIII captured in plate.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
-
Platform
Microplate
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 1 x 96 tests 100X Streptavidin-Peroxidase Conjugate 1 x 80µl 10X Diluent M Concentrate 1 x 30ml 20X Wash Buffer Concentrate 2 x 30ml 50X Biotinylated Human Apolipoprotein CIII Antibody 1 x 120µl Apolipoprotein CIII Microplate (12 x 8 well strips) 1 unit Apolipoprotein CIII Standard 2 vials Chromogen Substrate 1 x 7ml Sealing Tapes 3 units Stop Solution 1 x 11ml -
Research areas
-
Function
Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. -
Tissue specificity
Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine. -
Involvement in disease
Defects in APOC3 may be a cause of hyperalphalipoproteinemia (HYPALIP) [MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL). -
Sequence similarities
Belongs to the apolipoprotein C3 family. -
Post-translational
modificationsO-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- APOC3
- APO C3
- Apo CIII
see all -
Database links
- Entrez Gene: 345 Human
- Omim: 107720 Human
- SwissProt: P02656 Human
- Unigene: 73849 Human
Images
-
Sandwich ELISA - Apolipoprotein CIII (APOC3) Human ELISA Kit (ab154131)Standard curve of Hu APOCIII, with background signal subtracted (duplicates; +/- SD).
-
Sandwich ELISA - Apolipoprotein CIII (APOC3) Human ELISA Kit (ab154131)APOCIII measured in biological fluids, background signal subtracted (duplicates +/- SD). -
Sandwich ELISA - Apolipoprotein CIII (APOC3) Human ELISA Kit (ab154131)APOCIII detected in supernatants from cells after background signal was subtracted (duplicates +/- SD). -
Typical Standard CurveRepresentative Standard Curve using ab154131.
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab154131 has been referenced in 10 publications.
- Zhang T et al. HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia. Clin Biochem 79:14-22 (2020). PubMed: 32045574
- Reyes-Soffer G et al. Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 39:63-72 (2019). PubMed: 30580564
- Luo M et al. Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism. Lipids Health Dis 17:160 (2018). PubMed: 30021607
- Cheng X et al. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. J Biol Chem 292:3692-3705 (2017). PubMed: 28115523
- Reyes-Soffer G et al. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation 135:352-362 (2017). PubMed: 27986651
- Millar JS et al. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. J Lipid Res 58:1214-1220 (2017). PubMed: 28314859
- Luo M et al. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep 7:2312 (2017). PubMed: 28539597
- Gugliucci A et al. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis : (2016). PubMed: 27451002
- Lin Q et al. Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease. Drug Des Devel Ther 9:5421-31 (2015). ELISA . PubMed: 26491253
- Xiong X et al. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis 14:127 (2015). ELISA ; Human . PubMed: 26452348